Medical Beauty · Market Overview
The Japanese medical beauty market,why it is in focus now
In 2025, international patients reached 2.01 million, up 71% year over year. Japanese nationals were the second-largest nationality group at 29.8%, after China. Across all international patients, dermatology represented 62.9% of visits and plastic surgery 11.2%. Provider-level demand and profitability require separate validation. KHIDI 2025.
Market Size
Market size
The structure of Korea's international patient market and the share of the Japanese segment.
2.01M
International patients in 2025
+71%
Year-over-year growth in international patients
29.8%
Japanese share (second-largest nationality group)
62.9%
Dermatology share (all international patients)
11.2%
Plastic surgery share (all international patients)
No. 2
Japanese patient nationality rank in 2025
Growth Drivers
Demand hypotheses to validate
- How total cost, procedure scope, and aftercare affect clinic choice
- When K-beauty interest becomes clinic comparison and consultation intent
- How response time, Japanese-language support, payment, and interpretation affect drop-off
- How flight access and post-return care affect the visit decision
Competitive Landscape
Competitive structure
Registration counts and market growth alone do not establish an individual clinic's opportunity. Clinical fit, consultation operations, trust information, and contribution margin should be reviewed before competing on price.
- Large plastic surgery and dermatology clinics centered on Gangnam are investing early in Japanese-language marketing
- High dependence on acquisition agencies (insurance, packages) leaves fee burden and contract risk
- Unvalidated channel spending raises inquiry costs relative to ad spend
- Non-compliance can interrupt advertising and damage trust, so a pre-publication review process is required
Regulatory Environment
Regulatory environment
- Medical advertising: confirm pre-review requirements for each legally covered medium before publication
- International patient acquisition registration: acquisition agencies must register with the provincial governor
- Acquisition fee caps: 30% for clinics, 20% for hospitals, 15% for tertiary general hospitals
- Applicable rules: review provider and advertiser location, audience, medium, and service scope for Korea and Japan
- Personal and health information protection: outbound transfer requirements must be confirmed
FAQ
Frequently asked questions
- Is there still opportunity in the Japanese medical beauty market?
- The international patient market grew in 2025 and Japanese patients were the second-largest nationality group, but market growth does not guarantee provider-level profit. Clinical fit, Japanese-language consultation, booking, aftercare, and contribution margin require diagnosis.
- Which specialties are most favorable for acquisition?
- Dermatology represented 62.9% and plastic surgery 11.2% of visits across all international patients in 2025. These are not Japanese-only shares; each clinic must validate demand by specialty, procedure, price, and consultation capacity.
- Can we grow while staying compliant?
- It depends on the provider and service scope. The medical provider should remain the named advertiser and final approver, with pre-review status, claim evidence, testimonials, risk information, and acquisition-registration scope checked before publication.
Before entering the market, start with a diagnostic
Based on your clinic's specialties and objectives, we assess market opportunity and regulatory readiness.